This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=6 http://www.lsis.com/goto/r6/rss 2012-02-05T11:10:09+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 : To assess the effects of premenstrual disorders on health-related quality of life (HR-QOL), hobbies and social activities, and relationships with others in the multinational IMPACT study. |-| Patient. |-| Heinemann LA, Do Minh T, Filonenko A, Uhl-Hochgräber K. |-| 1 Berlin Center for Epidemiology and Health Research, Berlin, Germany 2 Bayer Schering Pharma AG, Berlin, Germany. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8088584 |-| Title: LTBP2 as a biomarker and diagnostic target |-| Inventors: Golz; Stefan (Essen, DE), Summer; Holger (Wuppertal, DE), Geerts; Andreas (Wuppertal, DE), Bruggemeier; Ulf (Leichlingen, DE), Albrecht-Kupper; Barbara (Wulfrath, DE), Klein; Martina (Dusseldorf, DE), Steppan; Sonja (Neu-Isenburg, DE), Ellinghaus; Peter (Melle, DE), D'Urso; Donatella (Dusseldorf, DE), Seewald; Michael (Berlin, DE), Milting; Hendrik (Bad Oeynhausen, DE) |-| Assignee: Bayer (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Introduction.? Oral contraceptives (OCs) induce mood and libido changes. Aim.? The aim of this study was to evaluate in young, eumenorrheic, healthy women the sexual behavior and the genital vascular effects of an OC containing 30?µg ethinylestradiol (EE) and 3?mg drospirenone (DRSP). Main Outcome Measures.? The main outcome measures are McCoy Female Sexuality Questionnaire (MFSQ), the labia minora thickness and vaginal introitus area, the pulsatility index (PI) of clitoral and (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=6 ScienceDaily (Dec. 21, 2011) New research suggests that, in people who don't currently have memory problems, those with smaller regions of the brain's cortex may be more likely to develop symptoms consistent with very early Alzheimer's disease. The study is published in the December 21, 2011, online issue of Neurology , the medical journal of the American Academy of Neurology. See Also: Health & Medicine Alzheimer's Research Healthy Aging Cholesterol Mind & Brain Alzheimer's Dementia (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8076355 |-| Title: 2-heteroarylcarboxylic acid amides |-| Inventors: Hendrix; Martin (Odenthal, DE), Bo.beta.; Frank-Gerhard (Sunninghill, GB), Erb; Christina (Kriftel, DE), Fle.beta.ner; Timo (Wuppertal, DE), Van Kampen; Marja (Neu-Isenburg, DE), Luithle; Joachim (Wulfrath, DE), Methfessel; Christoph (Wuppertal, DE), Wiese; Welf-Burkhard (Wermelskirchen, DE) |-| Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) |-| The invention relates to novel (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Topical glucocorticoids are highly anti-inflammatory effective but limited by their side effect potential, with skin atrophy being the most prominent one. Thus, determining the atrophogenic potential of novel compounds targeting the glucocorticoid receptor is important. Significant progress in the understanding of glucocorticoid receptor mediated molecular action has been made providing the basis for novel glucocorticoid receptor ligands with a potentially superior effect/side effect profile. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 BACKGROUND: 5-HT1A-R-agonist repinotan was shown to counteract a morphine-induced ventilatory depression but had pronociceptive effects at small doses (0.2 ?g/kg). It remained to be clarified (1) whether a moderate dose of repinotan, sufficient to stimulate spontaneous breathing, impairs antinociception if plasma concentration decreases over time, and if (2) moderate doses prevent ventilatory depression if given before the opioid. METHODS: A dose-response curve of the repinotan effects on (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 The objective of this analysis was to provide a comprehensive review of ovulation inhibition data of progestins currently available worldwide. This analysis may serve as a reference tool for research on new progestin molecules. |-| Contraception. |-| Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. |-| Bayer Schering Pharma, Müllerstr. 178, D-13342 Berlin, Germany; Universitätskliniken des Saarlandes, Frauenklinik, 66421 Homburg/Saar, Germany. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/1b3113/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in China 2011" report to their offering. China has one of the world's top ten largest pharmaceutical markets. The pharmaceutical industry in China is a booming sector as it covers not only pharmaceutical drugs, but also synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8053426 |-| Title: Progesterone receptor antagonists |-| Inventors: Fuhrmann; Ulrike (Berlin, DE), Schmidt; Anja (Berlin, DE), Cleve; Arwed (Berlin, DE), Petrov; Orlin (Berlin, DE), Garke; Gunnar (Berlin, DE), Pruehs; Stefan (Neuss, DE), Brudny-Kloeppel; Margarete (Berlin, DE), Rottmann; Antje (Berlin, DE), Hasselmann; Rainer (Berlin, DE), Schultze-Mosgau; Marcus (Berlin, DE), Moeller; Carsten (Berlin, DE) |-| Assignee: Bayer Schering Pharma AG (Berlin, DE) |-| The (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6528a9/neurodegenerative) has announced the addition of the "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth" report to their offering. Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=6 ScienceDaily (Nov. 2, 2011) Roughly 1 million people die by suicide each year. In the U.S., where nearly 36,000 people take their own lives annually, more than 4,600 victims are between the ages of 10 and 24, making suicide the third leading cause of death in this age group. See Also: Health & Medicine Mental Health Research Teen Health Accident and Trauma Mind & Brain Psychiatry Mental Health Depression Reference Suicide Self-harm Bulimia nervosa Sex education Youths treated at hospital (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today the appointment of Ron Cohen, M.D. and Paolo Pucci to its Board of Directors. In addition to their appointment as Directors, Dr. Cohen will serve on the Compensation Committee of the Board, and Mr. Pucci will serve on the Audit Committee. We welcome them to Dyax and look forward to their contributions as the Company continues to grow each of its three core (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3b5e71/mergers_and_acquis) has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering. Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market Explores the merits of mega-deal in contrast to a more measured (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 An analytical method using HPLC coupled with a charged aerosol detector (CAD) and a mass selective detector (MSD) was developed to characterize the non-ionic surfactant polysorbate 80 (PS 80). The molecular structure and heterogeneous composition due to isomers and various lengths of PEG-chains make it difficult to develop sensitive and specific analytical methods. Hence, there is only limited knowledge about the stability and purity of this compound. Polysorbate 80 does not possess any (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=6 Pharma Cloud World Europe 2011 is the premier event to understand, implement and leverage cloud computing technology taking place on the 7th - 10th November at Earls Court Conference Centre, London. The unrivalled speaker line up includes: GlaxoSmithKlineWellcome Trust Sanger InstituteCentocor Research & DevelopmentBroad InstituteAmazon Web ServicesEli LillyBayer ScheringNovartisand many more This is the single most important cloud computing in R&D event you can attend this year. We asked Dr (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=6 ScienceDaily (Oct. 20, 2011) With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. See Also: Health & Medicine Alzheimer's Research Healthy Aging Chronic Illness Mind & Brain Alzheimer's Dementia Intelligence Reference Dementia Dementia with Lewy bodies Multi-infarct (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=6 With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. But even when early memory problems suggest the potential for impending AD, the actual risk is variable. Some patients are at high risk while others are not. The challenge for doctors has long been to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Hepatocellular carcinoma (HCC) is increasingly being detected at an earlier stage, owing to the screening programs and regular imaging follow-up in high-risk populations. Small HCCs still pose diagnostic challenges on imaging due to decreased sensitivity and increased frequency of atypical features. Differentiating early HCC from premalignant or benign nodules is important as management differs and has implications on both the quality of life and the overall survival for the patients. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 NEWTON, Mass.-(BUSINESS WIRE)-Galectin Therapeutics (OTC: GALT), the leading developer of galectin inhibitor therapeutic compounds to treat fibrosis and cancer, today announced the election of Dr. Marc Rubin to its Board of Directors, effective today. Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of products for the treatment of central nervous system diseases. Dr. Rubin, Executive Chairman of Titan Pharmaceuticals, replaced S. Colin Neill who resigned (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved in several countries for thromboprophylaxis after elective hip or knee arthroplasty based on favorable benefit-risk profile and improved efficacy compared to enoxaparin in reducing the composite of symptomatic and asymptomatic deep vein thrombosis, nonfatal pulmonary embolism, and all-cause mortality. Given the potential therapeutic utility of factor Xa inhibition in arterial thrombosis, we evaluated the antithrombotic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/71299c/top_100_pharmaceut) has announced the addition of Plimsoll Publishing Ltd.'s "Top 100 Pharmaceutical Manufacturers (Global)" report to their extensive range of pharmaceutical publications. The latest report from Plimsoll Publishing is an in-depth financial evaluation of the top 100 pharmaceutical companies in the world. Using the unique Plimsoll method of analysis, each of the global top 100 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Pulmonary Hypertension database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 30,000 individuals working in Pulmonary Hypertension. http:/bit.ly/pTjsek. Top 10 Countries for Pulmonary Hypertension Research (ranked by number of senior researchers) (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 OBJECTIVE: In untreated Fabry patients without overt autonomic dysfunction and normal baroreflex sensitivity (BRS) at rest, BRS is impaired during orthostatic, sympathetic challenge but normalizes after enzyme-replacement therapy (ERT) (Hilz et al., J Hypertens 2010; 28:1438-1448). This study evaluated BRS during parasympathetic challenge with six cycles per minute metronomic deep breathing (MDB) in Fabry patients before and after ERT. METHODS: In 22 Fabry patients (28?±?8years), we (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=6 Health Network Communications are launching Pharma Cloud World Europe in November, Europe's leading cloud computing conference for senior pharmaceutical & biotech executives. This conference will discuss the opportunities and challenges, strategies and operational implementation of cloud computing for the pharmaceutical industry. We asked Dr Philip Groth, Managing Scientist at Bayer Schering Pharma what the major drivers for cloud implementation are: "Improving efficiency while saving (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 NEW YORK-(BUSINESS WIRE)-The U.S. Food and Drug Administration issued a statement today that the FDA remains concerned, but has not yet reached a conclusion, about the potential increased risk of blood clots from Drospirenone-containing birth control pills such as YAZ, YASMIN, BEYAZ, and OCELLA, among others. one of the nation s premier plaintiffs firms Preliminary results from an FDA-sponsored study of 800,000 women taking birth control pills shows that there is a 1.5 increased risk among (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8026239 |-| Title: Cell differentiation inducer |-| Inventors: Suzuki; Tsuneji (Mobara, JP), Ando; Tomoyuki (Mobara, JP), Tsuchiya; Katsutoshi (Mobara, JP), Nakanishi; Osamu (Pasadena, CA), Saito; Akiko (Mobara, JP), Yamashita; Takashi (Mobara, JP), Shiraishi; Yoshinori (Yokohama, JP), Tanaka; Eishi (Mobara, JP) |-| Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) |-| A method of treating a malignant tumor selected from the group consisting of leukemia, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 RuvBL1 (RuvB-like 1) and its homolog RuvBL2 are evolutionarily highly conserved AAA(+) ATPases essential for many cellular activities. They play an important role in chromatin remodeling, transcriptional regulation and DNA damage repair. RuvBL1 and RuvBL2 are overexpressed in different types of cancer and interact with major oncogenic factors, such as ?-catenin and c-Myc regulating their function. We solved the first three-dimensional crystal structure of the human RuvBL complex with a (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8022053 |-| Title: Oral solid dosage forms containing a low dose of estradiol |-| Inventors: Mueller; Kristina (Berlin, DE), Wagner; Torsten (Berlin, DE), Funke; Adrian (Berlin, DE), Zurth; Christian (Berlin, DE) |-| Assignee: Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) |-| The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 PHILADELPHIA-(BUSINESS WIRE)-The subhead that follows paragraph 4 should read Legal Resources for Injured Yaz Patients (sted Legal Resources for Injured Infuse Patients). Bayer failed to warn patients and doctors, we allege, that Yaz poses a greater risk of serious injuries than earlier generation birth control pills. The corrected release reads: FIRST YAZ BIRTH CONTROL INJURY TRIAL IN STATE COURT SCHEDULED TO COMMENCE IN JANUARY 2012 35 year old Woman Nearly Died From Blood Clot Allegedly (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0fc779/kidney_cancer_drug) has announced the addition of the "Kidney Cancer Drugs - Global Strategic Business Report" report to their offering. Kidney Cancer Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on Kidney Cancer Drugs' provides market analytics specifically for the Renal Cell Carcinoma (RCC) market, owing to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Meningococcal conjugate vaccines induce herd protection by preventing nasopharyngeal meningococcal acquisition, which is a prerequisite for invasive disease. Thus, meningococcal carriage epidemiology is important in understanding relationships between carriage and disease. A literature search traced information on meningococcal carriage in 27 EU countries. Meningococcal carriage prevalence differed within and between countries, varying across age groups, serogroup distribution and over time. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c172e3/iloprost_key_pat) has announced the addition of the "Iloprost - Key patent, SPC, and data exclusivity expiry (7 country coverage)" report to their offering. Iloprost - Key patent, SPC, and data exclusivity expiry (7 country coverage) Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 8008325 |-| Title: Plasma carboxypeptidase B inhibitors |-| Inventors: Buckman; Brad O. (Oakland, CA), Emayan; Kumar (Berkeley, CA), Islam; Imadul (Hercules, CA), May; Karen (Napa, CA), Bryant; Judi (Mill Valley, CA), Mohan; Raju (Encinitas, CA), West; Christopher (El Sobrante, CA), Yuan; Shendong (San Ramon, CA) |-| Assignee: Bayer Schering Pharma AG (Berlin, DE) |-| Compounds of the following formula (I), for example: #STR00001# wherein R.sup.1, R.sup.2, R.sup.3, and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=6 25 August 2011 - Sirtex Medical Limited (ASX: SRX) today announced revenue from the sales of goods increased 9 per cent to $70.3 million for the period ended 30 June 2011 and the company will pay a fully franked dividend of 7 cents per share. As previously reported dose sales increased 19 per cent from 4,171 doses to 4,977 doses worldwide. Sirtex Chief Executive Officer, Mr. Gilman Wong, said, œThese good results reflect a growing awareness and acceptance of SIR-Spheres microspheres as a (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 What is already known about this subject ? Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesterol esters from the cardioprotective high density lipoprotein cholesterol (HDL-C) to the proatherogenic low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) leading to lower levels of HDL-C but raising the levels of proatherogenic LDL-C and VLDL-C. ? Inhibition of CETP is considered a potential (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=6 ScienceDaily (Aug. 10, 2011) A new study suggests that the relationship between brain shrinkage and memory loss in Alzheimer's disease changes across the age spectrum. The research is published in the August 10, 2011, online issue of Neurology , the medical journal of the American Academy of Neurology. See Also: Health & Medicine Healthy Aging Alzheimer's Research Elder Care Mind & Brain Alzheimer's Dementia Disorders and Syndromes Reference Dementia with Lewy bodies Dementia Brain damage (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Introduction.? Phosphodiesterase (PDE) isoenzymes have been shown to play a role in the control of human male genital tissues. There are hints from basic research and clinical studies that PDE5 inhibitors may have the ability to retard the male ejaculatory response. While the expression of PDE isoenzymes in the human seminal vesicles (SVs) has been described, the distribution of cyclic adenosine monophosphate (AMP)- and cyclic guanosine monophosphate (GMP)-PDEs has not yet been investigated. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 MANSFIELD, Mass.-(BUSINESS WIRE)-Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the start of patient enrollment in the ev3 DEFINITIVE ¢ AR (Anti-Restenosis) study Imelda Hospital in Belgium with Dr. Patrick Peeters. DEFINITIVE AR continues our commitment to improve clinical outcomes and further the use of plaque excision as a frontline therapy for P.A.D. patients. DEFINITIVE AR is a European pilot study designed to address the challenge of restenosis (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 7977325 |-| Title: 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents |-| Inventors: Schwede; Wolfgang (Glienicke, DE), Kuenzer; Hermann (Berlin, DE), Ter Laak; Antonius (Berlin, DE), Bader; Benjamin (Berlin, DE), Hillig; Roman (Hamburg, DE), Moenning; Ursula (Woltersdorf, DE), Schmitz; Arndt (Berlin, DE), Zopf; Dieter (Berlin, DE) |-| Assignee: Bayer Schering Pharma AG (Berlin, DE) |-| This (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=6 United States Patent: 7977485 |-| Title: 2-heteroaryl carboxamides |-| Inventors: Luithle; Joachim (Wulfrath, DE), Bo.beta.; Frank-Gerhard (Berkshire, GB), Erb; Christina (Kriftel, DE), Hafner; Frank-Thorsten (Wupertal, DE), Schnizler; Katrin (Rodenbach, DE), Fle.beta.ner; Timo (Wuppertal, DE), van Kampen; Marja (Dusseldorf, DE), van der Staay; Franz-Josef (Dronten, NL) |-| Assignee: Bayer Schering Pharma Aktiengesellshaft (Berlin, DE) |-| The invention relates to novel 2-heteroaryl (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 In gene prediction, studying phenotypes is highly valuable for reducing the number of locus candidates in association studies and to aid disease gene candidate prioritization. This is due to the intrinsic nature of phenotypes to visibly reflect genetic activity, making them potentially one of the most useful data types for functional studies. However, systematic use of these data has begun only recently. 'Comparative phenomics' is the analysis of genotype-phenotype associations across species (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Introduction.? The prevalence of erectile dysfunction (ED) is increased in men with metabolic syndrome compared with the general population. Aim.? The aim of this study was to evaluate the efficacy and safety of vardenafil vs. placebo in men who had ED and metabolic syndrome. Methods.? This was a 12-week, double-blind, randomized, multicenter, parallel-group, placebo-controlled prospective study in men with ED and metabolic syndrome (assessed by the International Diabetes Federation (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=6 Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug. In order to recognize at an earlier stage which side effects are associated with the use of new cancer drugs, a research group under the guidance of the Goethe University has (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=6 ScienceDaily (July 19, 2011) Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug. In order to recognize at an earlier stage which side effects are associated with the use of new cancer drugs, a research group under the guidance (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Objectives: Testosterone has a spectrum of effects on the male organism. This review attempts to determine, from published studies, the time-course of the effects induced by testosterone replacement therapy from their first manifestation until maximum effects are attained. Design: Studies in PubMed on testosterone replacement so far providing information on time course. Results: Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, no further increments beyond. Changes in (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 In humans, dehydroepiandrosterone (DHEA), with its sulfate, is the most abundant adrenal steroid, whereas the rat adrenals are not capable of synthesizing this steroid. Circulating concentrations of DHEA sulfate lie in the millimolar range and those of DHEA in the subnanomolar range. DHEA exerts protective potential during vascular remodeling, although the underlying mechanisms of this protection are imperfectly defined. We hypothesized that physiological doses of DHEA alter signaling pathways (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=6 Drospirenone (DRSP) is a contraceptive drug substance with challenging physicochemical properties, due to insufficient solubility in aqueous and oil-based vehicles as well as low chemical stability in aqueous fluids. Although it is one of the most popular orally used progestins, no parenteral long-acting contraceptive containing the drug substance is marketed. An oil-based DRSP microcrystal suspension (MCS) might be an attractive formulation option. The main focus of this study was to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fb8b6d/product_profiles) has announced the addition of the "Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants" report to their offering. Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=6 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e0156e/testosterone_repla) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. Testosterone Replacement Therapy (TRT) - Global Strategic Business Report This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following (…)